Congress funds study to prevent TB transmission through organ transplants
H.R. 9561 — Shandra Eisenga TB Study Act of 2026 · Filed by John Moolenaar (R-MI) · 2 cosponsors · Introduced Jun 30, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Secretary of Health and Human Services to study whether a reliable test can be developed to detect tuberculosis in tissue from deceased donors, with the goal of improving organ and tissue transplant safety. The study must be completed within 2 years, involve consultation with the NIH, CDC, FDA, and organ procurement organizations, and result in a congressional report with recommendations within 3 years.
Why we flagged it
The bill is a straightforward appropriations-backed research mandate with no regulatory, tax, or private-benefit mechanisms. It directs a federal agency to conduct a feasibility study on a specific public-health problem (TB detection in cadaver tissue) and report findings to Congress.
What the text implies
- The study's recommendations may eventually lead to new FDA regulatory requirements for organ and tissue banks, potentially increasing compliance costs for procurement organizations and tissue banks — a secondary effect not explicit in the bill itself.
- Naming the bill after Shandra Eisenga (a deceased individual) suggests a personal or memorial motivation, though the bill text does not explain the connection or whether Eisenga was affected by TB transmission through transplant.
Who stands to gain
organ procurement organizations (study participants and potential future implementers); tissue banks (study participants and potential future implementers); medical device/diagnostic companies (if a test is eventually developed and commercialized)